Source of business for biosimilars in immunology
As of August 2023, there were 40 FDA-approved biosimilar products, including 25 commercially available products and four with interchangeable status.1 Adoption...
Travis Ruch
Principal
Travis Ruch is a principal in the Life Sciences Practice at CRA. Dr. Ruch has experiences across commercial strategy with a focus on analytics and development of pipeline assets. He has expertise across a wide variety of therapeutic areas including rare disease, immunology, pulmonary disease, kidney disease, CNS disorders, and metabolic conditions.
Prior to joining CRA Dr. Ruch worked as a research scientist investigating cell biology, infectious disease, and cystic fibrosis.
Credentials
Get In Touch
Travis Ruch